Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study

Yi Guo, Kelsie Cowman, Mei Chang, Hongkai Bao, Austin Golia, Terrence Mcsweeney, Linda Bard, Roxanne Simpson, Erin Andrews, Liise anne Pirofski, Priya Nori

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Monoclonal antibodies (mAb) prevent COVID-19 progression when administered early. We compared mAb treatment outcomes among vaccinated and unvaccinated patients during Delta wave and assessed the feasibility of implementing stricter eligibility criteria in the event of mAb scarcity. Methods: We conducted a retrospective observational study of casirivimab/imdevimab recipients with mild-to-moderate COVID-19 infection in an emergency department or outpatient infusion center (July 1–August 20, 2021). Primary outcome was all-cause hospital admission within 30 days post-treatment between vaccinated vs. unvaccinated patients during Delta surge in the Bronx, NY. Results: A total of 250 patients received casirivimab/imdevimab (162 unvaccinated vs. 88 vaccinated). The median age was 39 years for unvaccinated patients, and 52 years for vaccinated patients (p < 0.0001). The median number of EUA criteria met was 1 for unvaccinated and 2 for vaccinated patients (p < 0.0001). Overall, 6% (15/250) of patients were admitted within 30 days post-treatment. Eleven unvaccinated patients (7%) were admitted within 30-days compared to 4 (5%) vaccinated patients (p = 0.48). Conclusions: All-cause 30-day admission was not statistically different between vaccinated and unvaccinated patients. When federal allocation of therapies is limited, programs must prioritize patients at highest risk of hospitalization and death regardless of vaccination status.

Original languageEnglish (US)
Article number645
JournalBMC Infectious Diseases
Volume22
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • Casirivimab/imdevimab
  • Coronavirus disease 19
  • COVID-19
  • Delta variant
  • Monoclonal antibody
  • SARS-CoV-2 variant B.1.617.2
  • Unvaccinated
  • Vaccinated
  • Vaccination

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study'. Together they form a unique fingerprint.

Cite this